396 studies found for:    Open Studies | Interventional Studies | melanoma
Show Display Options
Download search resultsDownload the search results for:
Open Studies | Interventional Studies | melanoma (396 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting FDG-PET in Advanced Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Radiation: [18F]fluorodeoxyglucose;   Other: Molecular assays on biopsied tissue;   Device: positron emission tomography;   Device: computed tomography
2 Not yet recruiting Combi-Neo Study for Stage IV Melanoma
Conditions: Melanoma;   Malignant Melanoma Stage IV;   Metastatic Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Procedure: Surgery
3 Recruiting Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
4 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
5 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
6 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
7 Recruiting Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention: Drug: Pazopanib and Paclitaxel
8 Recruiting Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: Axitinib
9 Not yet recruiting Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Conditions: Stages III Skin Melanoma;   Stages II Skin Melanoma;   Stage IB Skin Melanoma
Interventions: Drug: Propranolol hydrochloride;   Drug: Placebo pill
10 Recruiting Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab
11 Recruiting INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Drug: IDO1 inhibitor INCB024360;   Biological: MELITAC 12.1 peptide vaccine;   Other: laboratory biomarker analysis
12 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Carcinoma of Unknown Primary;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: recombinant flt3 ligand;   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Biological: neoantigen-based melanoma-poly-ICLC vaccine;   Other: laboratory biomarker analysis;   Other: pharmacological study
13 Recruiting Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Liver Metastases;   Lung Metastases;   Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Biological: ipilimumab;   Radiation: stereotactic radiosurgery;   Other: laboratory biomarker analysis
14 Recruiting Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: fluorescein sodium injection;   Procedure: diagnostic microscopy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
15 Not yet recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
16 Recruiting Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: Montanide ISA 51 VG;   Biological: MART-1 antigen;   Other: laboratory biomarker analysis;   Biological: Gag:267-274 peptide vaccine;   Drug: resiquimod
17 Recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: cabozantinib-s-malate;   Drug: temozolomide;   Drug: dacarbazine;   Other: laboratory biomarker analysis
18 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Recruiting Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: axitinib;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Procedure: positron emission tomography
20 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: riluzole;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years